本帖最后由 老马 于 2012-1-13 21:20 编辑
2 O2 C# P: {( {) l2 b, \4 w7 [. q" H8 G& ~' h3 l
爱必妥和阿瓦斯丁的比较+ p2 d! o" L1 ^ T- k p1 G
g" d2 U9 G! N: uhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 G; n0 y& f2 d- |
: o. z- k1 k( [- ]# G, k
( n3 u9 B& H$ }6 D
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( A @, R" l( z& R- e
==================================================# z* t( U5 s* B6 z# u: t
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# w) @' U; g3 IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# j1 `- e9 n2 _& b EResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.0 p- e# M$ H. C8 I, N/ K
|